Does systemic thrombolytic therapy reduce mortality and PE recurrence in patients with acute PE?
Systemic thrombolysis improves mortality and reduces recurrence in acute PE but at the cost of increased major and intracranial hemorrhage, with no significant mortality benefit in hemodynamically stable patients.
Thrombolytic therapy reduces total mortality, PE recurrence, and PE-related mortality in patients with acute PE. The decrease in overall mortality is, however, not significant in haemodynamically stable patients with acute PE. Thrombolytic therapy is associated with an increase of major and fatal or intracranial haemorrhage.
Marti et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: